NCT03760666 - A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

February 9, 2021

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Brequinar/Brequinar + Ribavirin

The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.

Trial Locations (6)

Cleveland Clinic Lerner College of Medicine, Cleveland

The University of Texas MD Anderson Cancer Center, Houston

City of Hope, Duarte

Massachusetts General Hospital, Boston

Beth-Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston